Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial. Issue 7 (17th May 2020)

• Record Type: Journal Article
• Authors: Rios‐Romenets, Silvia; Lopera, Francisco; Sink, Kaycee M.; Hu, Nan; Lian, Qinshu; Guthrie, Heather; Smith, Jillian; Cho, William; Mackey, Howard; Langbaum, Jessica B.; Thomas, Ronald G.; Giraldo‐Chica, Margarita; Tobon, Carlos; Acosta‐Baena, Natalia; Muñoz, Claudia; Ospina, Paula; Tirado, Victoria; Henao, Eliana; Bocanegra, Yamile; Chen, Kewei; Su, Yi; Goradia, Dhruman; Thiyyagura, Pradeep; VanGilder, Paul S.; Luo, Ji; Ghisays, Valentina; Lee, Wendy; Malek‐Ahmadi, Michael H.; Protas, Hillary D.; Chen, Yinghua; Quiroz, Yakeel T.; Reiman, Eric M.; Tariot, Pierre N.;
• Is Part Of: Alzheimer's & dementia. Volume 16:Issue 7(2020)
• Page Start: 1023
• Page End: 1030
• Publication Date: 2020-05-17
• Subjects: Alzheimer's disease -- autosomal‐dominant Alzheimer's disease -- baseline data -- clinical trial -- crenezumab -- Alzheimer's Prevention Initiative -- preclinical Alzheimer's disease -- preclinical -- prevention; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12109
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who receive placebo. Methods: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non‐carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. Results: We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non‐carriers, 30 to 53 years of age. Carriers were significantly younger than non‐carriers ((mean age ± SD) 37 ± 5 vs 42 ± 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 ± 1.4 vs 29.2 ± 1.0), and had consistently lower memory scores. Discussion: Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non‐carriers. Their demographic characteristics are representative of the local population.